Brief: Rallybio Announces Proof-Of-Concept Achieved For Rlyb212, A Novel Monoclonal Anti-Hpa-1A Antibody To Prevent Fetal And Neonatal Alloimmune Thrombocytopenia
06/03/2023 12:36
March 6 (Reuters) - Rallybio Corp RLYB.O :
* RALLYBIO ANNOUNCES PROOF-OF-CONCEPT ACHIEVED FOR RLYB212,
A
NOVEL MONOCLONAL ANTI-HPA-1A ANTIBODY TO PREVENT FETAL AND
NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
* RALLYBIO CORP- CLINICAL FINDINGS AND SAFETY PROFILE
CONSISTENT
WITH PREVIOUSLY REPORTED DATA
Source text for Eikon: ID:nBw7KvlC9a
Further company coverage: RLYB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rallybio
See all newsNASDAQ RESUMED AT 08:48 AM
Brief: Rallybio Corporation And Avenzo Therapeutics Announce Merger Agreement To Advance Next-Generation Oncology Therapies And $215 Million Concurrent Private Placement
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE-Mirum Pharma
U.S. STOCKS ON THE MOVE-Mirum Pharma, eBay, FedEx